搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
2 小时
This US stock is crushing Nvidia's performance this year: Is it too late to buy?
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
7 小时
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
clinicaltrialsarena
2 天
Keytruda beaten by Summit’s bispecific in NSCLC
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
2 天
Iranian Immigrant Becomes Billionaire As Her Biotech Firm’s Stock Soars
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
ThePrint
2 天
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s ...
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
3 天
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
BioSpace
4 天
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
4 天
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That ...
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...
labiotech
4 天
Two targets, one solution: The rise of bispecific antibodies
Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...
Investor's Business Daily on MSN
5 天
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
5 天
肠癌新希望:双特异性抗体为MSS型mCRC带来治疗新选择!
你是否对转移性结直肠癌(mCRC)的治疗现状感到困惑?转移性结直肠癌是结直肠癌的一种晚期形式,患者往往面临着有限的治疗选择。然而,在刚刚结束的2024年欧洲肿瘤内科学会(ESMO)年会上,中山大学附属第六医院的邓艳红教授发布了一个令人振奋的研究成果:由双特异性抗体Ivonescimab联合FOLFOXIRI方案为微卫星稳定(MSS)型mCRC患者提供了新的治疗道路。
5 天
Here's Why Everyone's Talking About Summit Therapeutics
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈